ImmuPharma plc (AIM: IMM) has appointed Kymos Group as its bioanalytical contract research organisation partner for the development of Kapiglucagon, its proprietary glucagon prodrug for Type 1 diabetes applications.
Kymos was selected following a competitive tender process and will support the development and validation of regulated bioanalytical methods for Kapiglucagon, including analysis of samples generated during non-clinical and Phase 1 clinical studies.
The appointment follows ImmuPharma’s recent selection of Thermo Fisher as its CMC partner and Bachem AG as API manufacturing partner, further building out the development infrastructure for the programme.
Kapiglucagon is being developed to overcome limitations associated with native glucagon, including poor solubility and formulation stability, with potential applications in dual-hormone artificial pancreas systems and other glucagon-based therapies.
ImmuPharma is also evaluating a potential 505(b)(2) regulatory pathway in the US, subject to FDA confirmation, which could allow the programme to leverage existing data on native glucagon.
Joan Puig de Dou, Chief Executive Officer of Kymos Group, said:
“We are proud to support ImmuPharma in the development of Kapiglucagon, bringing our expertise in peptide bioanalysis to this promising program. Our company and team are fully committed to early-stage projects, empowering start-ups and biotech’s with tailor-made support of the highest quality standards, as they advance through pre-clinical and clinical stages.”
